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Abstract
Background: Schizophrenia and bipolar disorder are severe mental illnesses that can have a significant disabling
impact on the lives of people. Psychosocial interventions that stress hope and recovery as a part of a multi-
dimensional approach are possibly indicated to support people with severe mental illness in facilitating recovery.
Illness Management and Recovery (IMR) is a curriculum-based psychosocial intervention designed as structured
program with a recovery-oriented approach. The aim of IMR is to rehabilitate people with severe mental illnesses
by helping them acquire knowledge and skills in managing their illness and achieve personal recovery goals.
Previous randomised clinical trials indicate that IMR can be implemented with a good effect and a high fidelity
though further trials are crucial to demonstrate the potential effectiveness of IMR.
Methods/Design: The trial design is a randomised, assessor-blinded, multi-centre, clinical trial of the IMR program
compared with treatment as usual for 200 participants diagnosed with schizophrenia or bipolar disorder under the
care of two community mental health centres in the Capital Region of Denmark. The primary outcome is level of
functioning at the end of treatment. The secondary outcomes are disease symptoms; use of alcohol/drugs;
individual meaning of recovery; hope; hospital admissions and out-patient psychiatric treatment at the end of
treatment and the abovementioned and level of functioning at follow-up 21 months after baseline.
Discussion: If the results of this trial show IMR to be effective these positive results will strengthen the evidence of
IMR as an effective comprehensive psychosocial intervention with a recovery-oriented approach for people with
severe mental illness. This will have significant implications for the treatment and recovery of people with severe
mental illness.
Trial registration: Registration number NCT01361698.
Background
Schizophrenia and bipolar disorder are severe mental ill-
nesses that impact people’s lives in many disabling
aspects. Research indicates that medication alone is not
sufficient to help people with these diagnoses but has to
be a part of a multi-dimensional approach complemen-
ted with evidence-based psychosocial interventions in a
more comprehensive rehabilitation model [1,2]. Psycho-
social interventions that stress coping and personal
goals may contribute to facilitating recovery from the
profound functional and social deficits characterising
people with schizophrenia and bipolar disorder [3-5].
A recovery-oriented approach to these severe mental
illnesses holds that individuals are more than the sum of
their symptoms and that recovery involves a redefinition
of one’s illness as only one aspect of a multi-dimen-
sional sense of self [6].
Illness Management and Recovery (IMR) is a curricu-
lum-based, standardized program based on a recovery-
oriented approach to rehabilitation for people with
severe mental illnesses. The program is designed by Kim
Mueser et al. as an evidence-based practice based on the
principles of recovery to help people with severe mental
illnesses to set individual meaningful goals for their lives
and gain illness self-management skills and thereby con-
tribute to their individual recovery-process [7]. By col-
lecting the evidence of different empirically supported
practices including psycho-education, relapse
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adherence, coping skills training and social training,
IMR was developed as a full-ranged rehabilitation pro-
gram and consolidated into a single standardised pro-
gram for study and dissemination.
The theoretical foundation for the IMR program is the
trans-theoretical model and the stress-vulnerability
model. The trans-theoretical model assumes that human
change developed over a series of stages and by motivat-
ing people in the stage they are in through the IMR pro-
gram they can easier succeed in achieving their own
personal recovery goals [8,9]. The stress-vulnerability
model builds on the assumption that the course of
severe mental illness is determined by an interaction of
biological vulnerability, stress and coping. The aim of
IMR is to interrupt the circle of stress and vulnerability
that leads to poor functioning and relapse [10,11], see
Figure 1.
The core values of IMR are hope, personal choice, col-
laboration, respect, and recognizing people as experts in
their own experience of mental illness. First and fore-
most, the process of teaching Illness Management and
Recovery involves conveying a message of hope and
optimism, so that people with mental illness believe that
they can reach their own goals and begin a progress of
recovery. Non-controlled studies of IMR have provided
some support for the effectiveness and feasibility of the
program [12-14]. The effectiveness has been tested in a
few randomised trials with various settings [15-18] and
these trials indicate that IMR in group level can be
implemented with a good effect and a high fidelity to
the program curriculum [19,20]. Due to methodological
limitations in the previous trials regarding the blinding
process, follow-up assessments and the power of the
sample size further trials are crucial to prove the effect.
In the present IMR trial, the following alternative
hypotheses will be tested: Patients in the IMR program
will have improved at least 6 points on the Global
Assessment of Function scale (GAF-F) compared with
patients receiving treatment as usual at follow-up 9
months after baseline. Furthermore, the participants in
the IMR program will show a greater improvement after
9 months in relation to symptoms, drug/alcohol addic-
tion, relapse, rehospitalisation and treatment, knowledge
about their mental disease, coping strategies, recovery
and hope. Moreover the difference between the inter-
vention groups will be sustained 21 months after
baseline.
Methods/Design
T h et r i a ld e s i g ni sar a n d o mised, assessor-blinded,
multi-centre, clinical trial of the IMR program com-
pared with treatment as usual in 200 participants diag-
nosed with schizophrenia or bipolar disorder under the
care of two community mental health centres in the
Capital Region of Denmark.
From January 2011 to December 2013 IMR will be
tested in two community mental health centres with the
participation of 200 patients. The duration of the trial
will be four years. Recruitment to the trial has begun in
January 2011 and is due for completion in February
2012. The intervention will start March 2011 and the
follow-up assessments in November 2011. The partici-
pants will take part in the trial for the baseline inter-
view, and for the follow-up interviews by 9 and at 21
months (one year after the intervention is ended). More-
over a naturalistic follow-up is planned in a period of
ten years to evaluate any long-term effects. After the 21
months of follow-up the patients allocated to the con-
trol group will be offered IMR, if the program is shown
to be effective.
The experimental intervention
Patients randomised to the experimental intervention
will be offered IMR plus ‘treatment as usual’. The details
of the IMR program has been described elsewhere [21],
but will be briefly outlined below. The program is orga-
nised into 11 curriculum topic areas: recovery strategies,
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Figure 1 The theoretical foundation for Illness Management
and Recovery. The trans-theoretical model and the stress-
vulnerability model are the theoretical underpinning of the IMR
program.
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ity model, building social support, using medication
effectively, drug and alcohol use, reducing relapses,
healthy lifestyle, coping with stress, coping with pro-
blems and symptoms, and getting your needs met in the
mental health system. The first topic area is an explana-
tion of the concept of recovery followed by an identifi-
cation of personal recovery goals related to the
individuals’ own meaning of recovery. While the first 10
modules have been part of the IMR manual [22] from
the start, the 11th module on healthy lifestyle is added
later and has not been tested previously. We include
this module in the IMR program on the recommenda-
tion of the founders of the program (personal communi-
cation with Professor Kim Mueser, Dartmouth
University, USA).
IMR can be provided in an individual or group for-
mat, and generally lasts between four and ten months
with a series of weekly sessions where mental health
practitioners help the participants to develop persona-
lized strategies for managing their mental illness and
moving forward in their lives. Every session has the
same routine, which means that the whole program is
following a structured pattern. The curriculum topic
areas are taught by IMR facilitators using a combination
of educational, motivational, and cognitive-behavioural
teaching strategies and homework assignments devel-
oped collaboratively with the participant. With the par-
ticipants’ consent, significant others (e.g. family, friends)
are encouraged to be involved in helping participants
learn self-management strategies and pursue their per-
sonal goals. In the program the participant’s individual
goals are often broken down into smaller steps to facili-
tate a continuously progress towards achieving the
goals.
In this Danish trial IMR will be implemented in group
format with 10 patients assigned to each group and two
IMR facilitators, and the IMR program will require nine
months of weekly sessions to complete. The curriculum
of IMR has been translated into Danish prior to the
intervention.
To ensure the fidelity of the intervention at the com-
munity mental health centres the IMR facilitators will:
■ Be experienced mental health clinicians with all
together at least four days course in teaching IMR.
The teaching will be given prior to the intervention,
a n da g a i na f t e rs i xm o n t h sa n di fn e e da g a i na f t e r
one year by a well-experienced IMR educator from
USA (The Mental Health Center of Greater Man-
chester, New Hampshire).
■ Receive supervision from the well-experienced
IMR educator via an Internet connection to begin
with every second week and later on once a month.
■ Be involved in a network group for all IMR facili-
tators, formed to support the implementation of
IMR in the two community mental health centres.
■ Be evaluated by a trained IMR facilitator from the
other community mental health centre halfway
through each IMR course using the IMR Fidelity
Scale. The IMR Fidelity Scale consists of 13 items
that are rated on a 5 point scale [22].
The control group
Patients randomised to the control group will get ‘treat-
ment as usual’ only. This means individual adapted
interdisciplinary treatment including medication, indivi-
dual support, occupational therapy, psycho-education
and group therapy. Some of the staff members that also
a r eI M Rf a c i l i t a t o r sh a v et h er o l eo fb e i n gp r i m a r yc a r e
provider both for participants in the IMR intervention
and in the control group. To ensure that the staff mem-
bers are following the principles of treatment as usual
when meeting patients in the control group, they can
consult a task force consisting of a well-experienced
psychiatrist only performing treatment as usual.
Inclusion and exclusion criteria
Eligible participants will be adults (age 18+) of both
sexes who are: 1) associated with one of the two partici-
pating community mental health centres; 2) diagnosed
following the ICD-10 criteria of schizophrenia or bipolar
disorder; 3) able to speak and understand Danish; 4) giv-
ing informed consent verbally and in writing.
Patients will be excluded if they have: 1) a guardian or
a forensic psychiatric arrangement; 2) comorbidity with
the ICD-10 criteria of the diagnoses of dementia or
mental retardation; 3) a large-scale substance abuse - if
later on the abuse is under control, inclusion in the trial
will be possible; 4) a current home of supported housing
- since the treatment as usual given to this group of
patients is significant different from patients living inde-
pendently; 5) a current involvement in a psycho-educa-
tional course - patients are eligible for participation in
the trial after the psycho-educational course has ended
if they meet the inclusion criteria at this point; 6) not
given informed consent.
Recruitment and randomisation
Patients will be recruited from two community mental
health centres in the Capital Region of Denmark: Fre-
deriksberg-Vanløse and Ballerup-Egedal-Herlev, respec-
tively. Each potential participant is interviewed with the
diagnostic tool Present State Examination by a psychia-
trist or a trained psychologist to evaluate whether the
patient meets the criteria of diagnosis. After informed
consent is obtained for each eligible patient the baseline
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ments the participants will be randomly allocated to
either IMR or continue with treatment as usual. To
secure concealment of the allocation sequence the ran-
domisation will be central and telephone-based through
The Copenhagen Trial Unit. The allocation sequence
will be computer-generated, using permuted blocks of a
varying block size with equal allocation to the two arms.
The allocation sequence is stratified by diagnosis and
community mental health centre.
Participant withdrawal
If the participant decides to withdraw from the trial they
can 1) participate in the baseline interview and then
withdrawal from the treatment but participate in the fol-
low-up interviews; 2) participate in the baseline inter-
view and then withdrawal from the treatment and not
participate in the follow-up interviews 3) withdraw from
the whole trial so that all data about them are deleted.
Assessments
At baseline, the participants’ socio-demographic infor-
mation on education, employment, marital status, clini-
cal diagnosis, suicide attempts, and earliest contract
with psychiatric services will be collected.
Primary and secondary outcome measures
The primary outcome of the trial is overall functioning
measured by Global Assessment of Function (GAF-F)
post-intervention - after nine months. The GAF scale
[23] can be divided into two scales GAF-F and GAF-S
(one that focuses on functioning and one that focuses
on symptoms) [24]. In this trial the focus of the primary
outcome is functioning which is why the GAF-F scale is
used. Information about the participant’sl e v e lo ff u n c -
tioning will be obtained from interviews with partici-
pants at baseline and follow-up.
The secondary outcomes include level of symptoms,
social functioning, personal recovery experience and
hope, substance abuse, use of services and suicide
attempts. This information is obtained through an inter-
view with an assessor blind to the allocation. The parti-
cipant fill in questionnaires about their personal
recovery and hope, the primary care provider (not
blinded to the allocation) fill in a questionnaire about
substance abuse, adverse events, and suicide attempts.
Information about service use is obtained trough the
hospital records. The measurements are chosen accord-
ing to a well-known distinction between clinical recov-
ery and personal recovery [25,26]. Clinical recovery
refers to the absence of symptoms, an improvement in
functioning and prolonged remission. Personal recovery
refers to living a fulfilling and hopeful life even with lim-
itations caused by illness. In this trial we have divided
the assessments of recovery in accordance with these
two perspectives.
Clinical recovery
All outcome measures to assess clinical recovery are
continuous scales. The overall level of symptoms is
assessed by the subscale of symptoms of the global mea-
surement Global Assessment of Function - Symptoms
(GAF-S) [24]. The Positive and Negative Syndrome
Scale (PANSS) [27] assesses the level of an severity of
positive and negative symptoms as well as the general
psychopathology. This scale is primary developed to
measure symptoms of people diagnosed with schizo-
phrenia but can be useful to people diagnosed with
bipolar disorder as well [28]. The scale is a 7-point rat-
ing instrument that consists of 30 items.
Hamilton Rating Scale for Depression scale assesses
the level of symptoms of depression. In this trial we use
the version of the scale that includes 6 items referred to
as Ham D6 [29]which is covering the core symptoms of
depression.
Young Mania Rating Scale (YMRS) [29,30] is an
instrument developed to rate severity of manic episodes.
The YMRS consists of 11 items and a severity rating is
assigned to each rating.
Personal and Social Performance (PSP) [31] is a scale
developed from the Social and Occupational Functional
Assessment Scale (SOFAS) to assess psychiatric patients
level of functioning [32]. The scale assesses four
domains of social functioning: socially useful activities,
personal and social relationships, self-care and disturb-
ing and aggressive behaviour. Besides giving more
detailed and varied information about the participants’
level of function, the PSP scale is used to secure the
reliability of the GAF score.
Personal recovery
Participants are answering questionnaires to assess
aspects of their personal recovery this includes continu-
ous scales of recovery, illness management, hope and
satisfaction with psychiatric services.
Illness Management and Recovery Scale (IMR Scale) is
a scale especially developed to the IMR program [33]. It
summarizes different areas in 14 items relevant to the
recovery process including personal goals, knowledge
about the illness, admissions, use of alcohol or drugs,
functioning, symptoms, stress and coping. The IMR
Scale exists in two separate versions: one for the patient
and one for the primary care provider.
Mental Health Recovery Measure (MHRM) [34] is a
measurement of recovery in a general level and not spe-
cific attached to the IMR program. MHRM includes dif-
ferent aspects related to the process of personal
recovery. It is a 30-item self-report scale designed to
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tal illnesses e.g. schizophrenia and bipolar disorder.
T h eA d u l tS t a t eH o p eS c a l e[ 3 5 ]i sas e l f - r e p o r ts c a l e
of hope and optimism. It consists of 6 items and is
rated on a scale from 1 to 8. The scale was psychometri-
cally tested in college students and in a community
sample, but has also been shown to be appropriate for
people with severe mental illnesses as well [36].
Clients Satisfaction Questionnaire [37] assesses the
participants’ satisfaction with the psychiatric services.
This information is relevant from both groups point of
views since satisfaction with services can explain even-
tual drop out and the level of effect on the other mea-
sures. The satisfaction of the clients also gives
indications of how the mental health community should
look like in the future according to its users.
Blinding
Assessments regarding clinical recovery will be con-
ducted by an assessor blind to treatment allocation. The
assessor will go through a profound assessment training
program. Issues concerning inter-rater reliability will
have no bearing on this trial since only one person will
be conducting the assessments. Due to the nature of the
intervention neither participants nor staff can be blinded
to allocation, but are strongly inculcated not to disclose
the allocation status of the participant at the follow up
assessments. An employee outside the research team
will feed data into the computer in separate datasheets
so that the researchers can analyse data without having
access to information about the allocation.
Monitoring for participant compliance
The use of treatment is registered for both the experi-
mental intervention group and the control group. This
is done to ensure the similarity of the treatment as
usual that both groups are offered. The attendance at
the IMR sessions is registered to monitor the participa-
tion compliance. All information regarding covariates,
primary outcome, secondary measures, use of psychia-
tric service and attendance at the IMR sessions is
recorded in a case record form. A view of the data col-
lection is listed in table 1.
Analysis
Power and sample size
We are planning a trial of the continuous response vari-
able, GAF-F, from independent control and experimen-
tal participants with one control per experimental
participant. A previous study involving psycho-education
in a Danish community mental health centre showed
that response within each participant group was nor-
mally distributed with a standard deviation of 15 [38].
In the few previous studies using IMR or elements of
IMR the effectiveness has been assessed by using the
total GAF score showing a difference of 6-10 points
[21,39]. Based on this knowledge we will conservatively
estimate the true difference in the experimental and
control group means to be 6 points on the GAF-F
score. Using this estimation will require a total of 200
participants to reject the null hypothesis that the popu-
lation means of the experimental and control groups are
e q u a lw i t hp r o b a b i l i t y( p o w e r )0 . 8 .T h et y p eIe r r o r
probability associated with this test of the null hypoth-
esis is 0.05. The power and sample size calculations
have been made using the PS Power and Sample Size
Calculations program version 3.0.34 [40].
The power of some the secondary measures has also
been estimated with a total number of 200 participants.
This showed that a sample size of 200 participants is
sufficient to show a relevant effect size in PSP, PANSS
and the IMR Scale corresponding to similar studies, see
table 2. The remaining secondary measures have not
been tested due to the fact that similar trials with these
outcomes could not be obtained. Thus, the results of
these analyses should be interpreted with caution, and
the analyses should be considered as exploratory.
Data analysis
The analysis will be performed by using the IBM SPSS
Statistics version 19 for Windows. The data analysis will
be based on the principle of intention-to-treat. The sig-
nificance level for the analysis of the primary outcome
and the secondary outcome will be 0.05.
Demographic variables will be listed in a table. The
primary outcome measure is the continuous measure-
ment GAF-F. The primary analysis of effectiveness will
compare GAF-F at 9 months. The secondary analysis
will compare effectiveness of the secondary outcome
measures at 9 months and GAF-F and the secondary
outcomes at 21 months. The analysis of differences
between groups will be conducted using t-tests and ana-
lysis of the variances will be conducted using ANOVA.
Repeated measures techniques may also be applied.
Dichotomous outcome assessments will be analysed
using logistic regression and paired dichotomous out-
comes will be analysed using McNemar tests, or using
logistic regression with random effects. Missing data is a
potential source of bias and therefore the operation of
multiple imputations will be used to address the issue of
missing values. An analysis of the drop-out will be con-
ducted to validate the complete case analyses.
Ethical considerations
All participants are offered treatment as usual, i.e. treat-
ment according to best practice and adapted to the indi-
vidual needs of the patient. The trial will follow the
international ethical guidelines of informed consent in
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given both verbally and in writing. The participants will
be informed about their rights to decline participation
or to withdraw with no consequences to their future
care or treatment. The participants will not receive a fee
for their participation.
Signed consent forms will be dated, with a copy being
given to the participant, and the original form kept with
Table 1 Data collection
Source of collection Assessments Time of recording
Baseline 9 months (post
intervention)
21 months (one year
follow up)
Obtained trough Interview Global Assessment of Functioning (GAF-F
and GAF-S)
XX X
Personal and Social Performance (PSP) X X X
Positive and Negative Syndrome Scale
(PANSS)
XX X
Hamilton Rating Scale for Depression (HAM-
D6)
XX X
Young Mania Rating Scale (YMRS) X X X
Primary treatment provider fill out
questionnaires
Alcohol and drug consumption X X X
Diagnose X
First contact with psychiatric service X
Suicide attempts X X X
Marital status X
Housing condition X
Education X
Employment X X X
Use of treatment as usual X X
IMR attendance - only for intervention
group
XX
Life-threatening conditions (other than
suicide)
XX
Illness Management and Recovery Scale -
staff version
XX X
Patient fill out questionnaires Illness Management and Recovery Scale -
patient version
XX X
Mental Health Recovery Measure X X X
Adult State Hope Scale X X X
Clients Satisfaction Questionnaire X X
Hospital records Suicide X X
Death (all causes) X X
Number of hospital admissions X X
Length of hospital admissions X X
Use of out-patient services X X
Table 2 Power calculations of PSP, PANSS and IMR Scale
Measure The level of
significance
Power St. deviation in a similar
study
Effect size in a similar
study
Minimum sample
size
Reference
PSP 0,05 0,8 14 7 128 Nasrallah et al. 2008 [40]
PANSS 0,05 0,8 11 5 154 Fowler et al. 2009 [41]
IMR
scale
0,05 0,8 0,5 0,41 48 Hasson-Ohayon et al.
2007[17]
Note: PSP: Personal and Social Performance; PANSS: Positive and Negative Syndrome Scale; IMR Scale: Illness Management and Recovery Scale.
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been reviewed and approved by The Ethics Committee
in the Capital Region of Denmark (registration number
H-1-2010-134), it is reported to the Danish Data Protec-
tion Agency and it is registered at http://www.clinical-
trials.gov (number NCT01361698).
Previous research does not indicate that IMR induces
risk to the participating patients. All adverse events e.g.
increase in symptoms, decrease in functioning, changes
in alcohol/drug consumption and incidents of suicide,
and also all beneficial events e.g. increase in level of
function, hope or progress in recovery will be registered
and reported. Participating in the Present State Exami-
nation, baseline and follow up interviews may cause
some disturbance to the participants, but will be
planned flexibly with possible breaks when needed. The
results from this trial will contribute with evidence to
improve treatment and rehabilitation of people diag-
nosed with schizophrenia and bipolar disorder. The
results will also contribute to future evidence in relation
to the IMR program. In the opinion of the research
team the pros greatly counterbalance the cons in this
trial.
Discussion
The IMR trial is a randomised clinical trial to evaluate
the effectiveness of the IMR-program for people diag-
nosed with schizophrenia and bipolar disorder in
according to their level of functioning.
In this design of testing the IMR program an impor-
tant factor is to insure the fidelity to the IMR program
curriculum, so that the IMR program is the taught the
same way, using the same slides and same topic areas
across the participating community mental health cen-
tres. A strength of this trial is therefore that all IMR
facilitators go through a specific course of education
prior to the intervention, have profound supervision
during the intervention and that we test the fidelity
using the IMR fidelity scale throughout the course of
each IMR group.
Another strength in the design of this trial is that a
solid sample size calculation has been made, so we will
be able to perform a data analysis with good strength
according to the primary outcome, GAF-F. Besides this
we have estimated the power of some the secondary
measures with a total number of 200 participants. This
showed that a sample size of 200 participants is suffi-
cient to show a relevant effect size in the secondary out-
come measurements PSP, PANSS and the IMR Scale
which will strengthen the results in these aspects.
Furthermore, the risk of selection bias related to alloca-
tion sequence generation and concealment is low, as the
randomisation is performed centrally according to a
computer-generated allocation sequence generation. The
fact that the assessor of the primary outcome is blinded
and that intention-to-treat analysis are going to be used
as a statistically approach i nt h ed a t aa n a l y s e sa r ea l s o
strengthening the design of this trial.
Some would argue that that there is a difference
between the level of functioning of the two diagnoses,
which is seen in studies comparing level of functioning
for in-patients, though literature about this issue is
inconsistent in their conclusions [41-43]. A recent study
from Norway comparing Global Assessment of Function
for the diagnoses schizophrenia and bipolar disorder in
a mixed study population of in-patients and out-patients
conclude that schizophrenia and bipolar disorder cannot
be viewed as categorically different [44]. In the design of
this trial we have carefully considered this aspect and
have chosen to mix patients with two the diagnosis,
since there some support of an equal level of function-
ing on the GAF score (it ranges from 51.79 to 53.00)
[24,38,45] for this trial population and since patients
included in the trial are admitted to the same treatment
unit reflected same level of functioning. However, to
secure that the compared groups are similar the alloca-
tion sequence is stratified by diagnosis and community
mental health centre. This way potential difference in
prognostics features between the two diagnoses and
community mental health centres are accounted for,
which increase the validity of comparison between the
intervention and control group.
A limitation in the design of this trial is that some of
the staff members both are IMR facilitators and at the
same time maybe have patients that get treatment as
usual. We have chosen not to force the patients to
change their primary care provider after the result ran-
domisation. This demands that the staff members have
a stringent separation of what is the treatment as usual
and what is treatment methods according to the IMR
concept. To handle situation where staff might be con-
fused of they are mixing the IMR concept with treat-
ment as usual they can consult a task force consisting of
a well-experienced psychiatrist only performing treat-
ment as usual.
A limitation to the trial design is that only the asses-
sor rating the factors associated to the aspects of clinical
recovery is blind to allocation. When investigating a
rehabilitation program like IMR it is not possible to
blind the participant or the staff, so this might increase
bias. The risk of bias could be seen according to the
assessments related to personal recovery which is rated
both by the primary care provider and by the participat-
ing patient since the awareness of the currently treat-
ment might bias the outcome. On the other hand we
think it is strength of this trial that we both get a sub-
jective view of recovery when the person in recovery are
to evaluate his/her own process and a more objective
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provider which have fulfilling knowledge of the patient
though close contact.
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